Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines

被引：47

作者：

Earl, Patricia L. ^{[1
]}

Cotter, Catherine ^{[1
,2
]}

Moss, Bernard ^{[1
]}

VanCott, Thomas ^{[2
]}

Currier, Jeffrey ^{[2
]}

Eller, Leigh Anne ^{[2
]}

McCutchan, Francine ^{[2
]}

Birx, Deborah L. ^{[2
]}

Michael, Nelson L. ^{[2
]}

Marovich, Mary A. ^{[2
]}

Robb, Merlin ^{[2
]}

Earla, Patricia L. ^{[2
]}

机构：

[1] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA

[2] Walter Reed Army Inst Res, Mil HIV Res Program, Rockville, MD USA

来源：

VACCINE | 2009年 / 27卷 / 42期

关键词：

MVA; HIV vaccine; Immune response; HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VITRO EXPRESSION; TYPE-1; SUBTYPE-C; T-CELL EPITOPES; ANKARA MVA; ENVELOPE GLYCOPROTEIN; IMMUNE-RESPONSES; RHESUS-MONKEYS; GAG-POL; PROTECTIVE IMMUNITY;

D O I：

10.1016/j.vaccine.2009.07.039

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Recombinant modified vaccinia virus Ankara (rMVA) expressing HIV-1 genes are promising vaccine candidates. Toward the goal of conducting clinical trials with one or a cocktail of recombinant viruses, four rMVAs expressing env and gag-pol genes from primary HIV-1 isolates representing predominant subtypes from Kenya, Tanzania, Uganda, and Thailand (A, C, D, and CRF01_AE, respectively) were constructed. Efficient expression, processing, and function of Env and Gag were demonstrated. All inserted genes were shown to be genetically stable after repeated passage in cell culture. Strong HIV-specific cellular and humoral immune responses were elicited in mice immunized with each individual vaccine candidate. The MVA/CMDR vaccine candidate expressing CRF01_AE genes has elicited HIV-specific T-cell responses in two independent Phase I clinical trials. Further testing of the other rMVA is warranted. Published by Elsevier Ltd.

引用

页码：5885 / 5895

页数：11

共 80 条

[51] Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys [J].

Liu, Jinyan ;

O'Brien, Kara L. ;

Lynch, Diana M. ;

Simmons, Nathaniel L. ;

La Porte, Annalena ;

Riggs, Ambryice M. ;

Abbink, Peter ;

Coffey, Rory T. ;

Grandpre, Lauren E. ;

Seaman, Michael S. ;

Landucci, Gary ;

Forthal, Donald N. ;

Montefiori, David C. ;

Carville, Angela ;

Mansfield, Keith G. ;

Havenga, Menzo J. ;

Pau, Maria G. ;

Goudsmit, Jaap ;

Barouch, Dan H. .

NATURE, 2009, 457 (7225) :87-91

[52] Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine [J].

Liu, JY ;

Wyatt, LS ;

Amara, RR ;

Moss, B ;

Robinson, HL .

VACCINE, 2006, 24 (16) :3332-3339

[53]

Mayr A., 1975, Infection, V3, P6, DOI DOI 10.1007/BF01641272

[54] HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis [J].

McElrath, M. Juliana ;

De Rosa, Stephen C. ;

Moodie, Zoe ;

Dubey, Sheri ;

Kierstead, Lisa ;

Janes, Holly ;

Defawe, Olivier D. ;

Carter, Donald K. ;

Hural, John ;

Akondy, Rama ;

Buchbinder, Susan P. ;

Robertson, Michael N. ;

Mehrotra, Devan V. ;

Self, Steven G. ;

Corey, Lawrence ;

Shiver, John W. ;

Casimiro, Danilo R. .

LANCET, 2008, 372 (9653) :1894-1905

[55] Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge [J].

Men, R ;

Wyatt, L ;

Tokimatsu, I ;

Arakaki, S ;

Shameem, G ;

Elkins, R ;

Chanock, R ;

Moss, B ;

Lai, CJ .

VACCINE, 2000, 18 (27) :3113-3122

[56] MAPPING OF DELETIONS IN THE GENOME OF THE HIGHLY ATTENUATED VACCINIA VIRUS MVA AND THEIR INFLUENCE ON VIRULENCE [J].

MEYER, H ;

SUTTER, G ;

MAYR, A .

JOURNAL OF GENERAL VIROLOGY, 1991, 72 :1031-1038

[57] FUSOGENIC MECHANISMS OF ENVELOPED-VIRUS GLYCOPROTEINS ANALYZED BY A NOVEL RECOMBINANT VACCINIA VIRUS-BASED ASSAY QUANTITATING CELL FUSION-DEPENDENT REPORTER GENE ACTIVATION [J].

NUSSBAUM, O ;

BRODER, CC ;

BERGER, EA .

JOURNAL OF VIROLOGY, 1994, 68 (09) :5411-5422

[58] Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV [J].

Ourmanov, I ;

Brown, CR ;

Moss, B ;

Carroll, M ;

Wyatt, L ;

Pletneva, L ;

Goldstein, S ;

Venzon, D ;

Hirsch, VM .

JOURNAL OF VIROLOGY, 2000, 74 (06) :2740-2751

[59] Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy [J].

Pereyra, Florencia ;

Addo, Marylyn M. ;

Kaufmann, Daniel E. ;

Liu, Yang ;

Miura, Toshiyuki ;

Rathod, Almas ;

Baker, Brett ;

Trocha, Alicja ;

Rosenberg, Rachel ;

Mackey, Elizabeth ;

Ueda, Peggy ;

Lu, Zhigang ;

Cohen, Daniel ;

Wrin, Terri ;

Petropoulos, Christos J. ;

Rosenberg, Eric S. ;

Walker, Bruce D. .

JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (04) :563-571

[60] Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity [J].

Peters, Barry S. ;

Jaoko, Walter ;

Vardas, Eftyhia ;

Panayotakopoulos, George ;

Fast, Patricia ;

Schmidt, Claudia ;

Gilmour, Jill ;

Bogoshi, Mampedi ;

Omosa-Manyonyi, Gloria ;

Dally, Len ;

Klavinskis, Linda ;

Farah, Bashir ;

Tarragona, Tony ;

Bart, Pierre-Alexandre ;

Robinson, Andrew ;

Pieterse, Colleen ;

Stevens, Wendy ;

Thomas, Richard ;

Barin, Burc ;

McMichael, Andrew J. ;

McIntyre, James A. ;

Pantaleo, Giuseppe ;

Hanke, Tomas ;

Bwayo, Job .

VACCINE, 2007, 25 (11) :2120-2127

← 1 2 3 4 5 6 7 8 →